Aurinia Pharmaceuticals (NASDAQ: AUPH) announced positive top-line results from the Phase 2b AURA-LV (AURA) clinical study in patients with active ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE